



## Neuland Q3FY22 income at Rs.238.4 crore

### EBITDA at Rs. 34.2 crore

Hyderabad, India, February 1, 2022 - Neuland Laboratories Limited (NLL) (NSE: NEULANLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the third quarter and nine months ended December 31, 2021.

**Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said,** *“The quarter gone past was impacted by a lower than anticipated revenue primarily due to the weak performance of the Prime business which was 20% lower than the quarterly average over the previous year. We have been impacted by customers’ issues on the market-share and inventory front for two of our key products. Having said that we have had our highest ever quarterly revenues from the CMS division, and we see growing utilization of Unit-3 for both GDS & CMS businesses.”*

In addition, **Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added** *“FY 22 has been a challenging year for us with volatility both on the revenue and cost fronts. While Q3 revenues have been impacted by the GDS business, the ongoing raw material and supply chain challenges have also tested our mettle. Given the circumstances and on-going investments for the future, profitability margins this quarter are not reflective of the businesses’ potential. On the CMS front, we are seeing good traction in new opportunities even as we are focussed on delivering the current projects which are exciting in terms of their potential.”*

## Financial Summary

Rs. crore								
Particulars	Q3FY22	Q2FY22	QoQ Growth (%)	Q3FY21	YoY Growth (%)	9MFY22	9MFY21	YoY Growth (%)
Total Income	238.4	258.1	(7.7)%	245.6	(2.9)%	699.4	693.7	0.8%
EBITDA	34.2	43.1	(20.6)%	46.7	(26.8)%	104.9	122.5	(14.3)%
EBITDA margin (%)	14.3%	16.7%	(240) bps	19.0%	(470) bps	15.0%	17.7%	(270) bps
PAT	12.7	20.3	(37.4)%	26.7	(52.3)%	41.7	63.1	(33.9)%
PAT margin (%)	5.3%	7.9%	(260) bps	10.9%	(560) bps	6.0%	9.1%	(310) bps
EPS (Basic) Rs.	9.9	15.8	(37.4)%	20.8	(52.3)%	32.5	49.2	(33.9)%

## Q3 FY22 Earnings Call

The company will conduct a one-hour Earnings call at **17:30 hrs. IST on Tuesday, February 1, 2022** where the management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please register on the Zoom link below:

[Zoom Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

## About Neuland Laboratories Limited

For over 38 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs and has filed over 903+ Regulatory filings in the US (60 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit [www.NeulandLabs.com](http://www.NeulandLabs.com).

**If you have any questions or require further information, please feel free to contact**

***IR Department at Neuland***

***Tel: +91 40 6761 1600***

***Email: [ir@neulandlabs.com](mailto:ir@neulandlabs.com)***

***Diwakar Pingle, Christensen***

***Email: [dpingle@christensenir.com](mailto:dpingle@christensenir.com)***